yervoy-navigation-2-jl

Article

  >YOUR STORIES, YOUR VOICE > EFFICACY: OS IN TOTAL POPULATION>TOOLS AND RESOURCES

Recent Videos
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Vinay K. Puduvalli, MD, is featured in this series.
Related Content
Management and Prevention of AEs Associated With Ponatinib Improved

Management and Prevention of AEs Associated With Ponatinib Improved

Jonah Feldman
December 12th 2024
Article
Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Positive Safety Data Enforces Elacestrant as Treatment Option in HER2– Breast Cancer

Positive Safety Data Enforces Elacestrant as Treatment Option in HER2– Breast Cancer

Gina Mauro
December 12th 2024
Article
A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis

Alex Biese
December 12th 2024
Article

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

Neoadjuvant HER3-DXd Maintains Response Rates with Fewer TRAEs in Breast Cancer

Neoadjuvant HER3-DXd Maintains Response Rates with Fewer TRAEs in Breast Cancer

Kristi Rosa
December 11th 2024
Article

For patients with HR–positive/HER2-negative breast cancer, neoadjuvant patritumab deruxtecan with or without letrozole showed antitumor activity.